The interaction between peptide ligands and cognate receptors governs magnitude, duration, and character of biological response. Understanding quantitative parameters - binding affinity, efficacy, signal bias, and kinetics - enables rational drug design, dose optimization, and clinical behavior prediction. This primer examines biophysical and cellular pharmacology principles with examples from GLP-1R, GHS-R, and opioid peptide systems.
Equilibrium Binding and Affinity Metrics
Equilibrium dissociation constant (Kd) quantifies ligand concentration at half receptor occupancy. Lower Kd = tighter binding. Related metrics: Ki (inhibition constant), EC50 (functional potency). For peptide-receptor pairs, typical Kd spans picomolar (oxytocin-oxytocin R, ~10pM) to micromolar (neuropeptide pairs). GLP-1 binds its R with Kd ~0.3-1nM - high affinity enabling physiological action at 5-15pM circulating concentrations.
Binding affinity does NOT equal functional potency. Ligand may bind tightly without activating (antagonist), or bind moderately but efficiently stabilize active conformation (high intrinsic efficacy).
Intrinsic Efficacy and Signal Bias
Intrinsic efficacy describes ability to stabilize active receptor conformation. Full agonists produce maximal system response; partial agonists submaximal even at full occupancy.
'Biased agonism' has transformed understanding: different ligands stabilize distinct active conformations engaging downstream pathways with varying efficiencies. At GLP-1R, some agonists strongly activate Galphas/cAMP (insulin secretion) while poorly recruiting beta-arrestin (internalization/MAPK). Others show opposite preference. Therapeutic implication: biased ligands could separate weight loss from glycemic effects.
Kinetic Parameters: Residence Time
Traditional emphasis on equilibrium parameters is giving way to kinetic recognition. Residence time (complex duration) often matters more than Kd for in vivo effect duration. Two ligands with identical Kd may have vastly different off-rates producing different durations. Semaglutide's once-weekly dosing partly reflects optimized binding kinetics.
Strategies prolonging residence time: conformational constraints (cyclization/stapling), non-natural amino acids for additional contacts, multivalent designs.
Allosteric Modulation
Allosteric ligands bind sites distinct from orthosteric pocket, modulating response to endogenous ligand. PAMs enhance; NAMs diminish. Advantages: preserved spatiotemporal patterns, ceiling effects (safety), subtype selectivity. For GHS-R, small-molecule PAMs enhance ghrelin-induced GH secretion without direct activation - preserving physiological pulsatility.
From Parameters to Clinical Dosing
Translating in vitro PD to clinical doses requires PK integration. Approximation: therapeutic plasma should exceed EC50 (preferably EC80-90) for meaningful fraction of dosing interval. Interindividual variation in receptor expression, clearance, competing endogenous ligands adds complexity. Biomarker-guided precision dosing represents aspirational future.
Key Findings:
- Kd defines binding tightness; typical peptide-receptor range pM to μM
- Biased agonism enables pathway-selective same-receptor drugs
- Residence time often > equilibrium affinity for effect duration
- Allosteric modulators offer ceiling effects and subtype selectivity
| Parameter | Definition | Typical Range | Relevance |
|---|---|---|---|
| Kd/Ki | Equilibrium affinity | 10pM - 10μM | Occupancy prediction |
| EC50 | Functional potency | Often >Kd | Dose-response positioning |
| Emax | Maximal capability | Full-partial spectrum | Ceiling determination |
| Residence Time | Complex duration | Seconds-hours | Dosing frequency |
| Bias Factor | Pathway selectivity | Quantifies divergence | Profile shaping |
References
- Kenakin T, Christopoulos A. 'Signaling Bias in Drug Discovery.' Nat Rev Drug Discov. 2024;23:845-863.
- Sykes DA, et al. 'Drug-Receptor Residence Time.' Nat Rev Drug Discov. 2023;22:789-810.
- Hothersall JD, et al. 'Biased GLP-1R Signaling.' Mol Pharmacol. 2024;105:234-248.
